Efficacy and Tolerability of Xalatan in Patients

N/ACompletedNCT00950690

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1,289 enrolled

Overview

Efficacy data was not collected or analyzed. This study did assess safety and tolerability of Xalatan.

* Efficacy data not collected or analyzed * Safety and tolerability of Xalatan assessed NA

Study Type

OBSERVATIONAL

Enrollment

1,289

Conditions

Glaucoma Ocular Hypertension

Interventions

Xalatan 0.005% eye dropsDRUG

ophthalmic solution dosed once daily for 3 months

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with ocular hypertension at least 22mg Hg * Patient must be over 18 years old Exclusion Criteria: * None listed in the protocol

Locations (3)

Pfizer Investigational Site

Alexandria, Egypt

Pfizer Investigational Site

Jeddah, Saudi Arabia

Pfizer Investigational Site

Umm Al Quwain City, United Arab Emirates

Outcomes

Primary Outcomes

Intraocular Pressure

Intraocular pressure was measured at each visit

Time frame: Screening, 10 days, 4 weeks and 12 weeks after beginning treatment

Humphrey Perimetry Visual Field

Analysis of visual field deficits for abnormalities.

Time frame: Visits 1 and 4

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.